Benzinga's Volume Movers

shares climbed 40.15% to $40.97. The volume of Prothena shares traded was 3383% higher than normal. Prothena's Phase I study of its treatment for Parkinson's disease met its primary end point for safety.

surged 21.93% to $56.26. The volume of Ctrip.com International shares traded 1148% higher than normal. Ctrip.com reported a narrower-than-expected loss for the fourth quarter.

shares moved up 18.12% to $13.10. The volume of Rally Software Development traded was 1015% higher than normal. Rally Software reported a Q4 loss of $0.28 per share on revenue of $24.6 million.

shares rose 6.74% to $462.88. The volume of Biogen Idec shares traded was 633% higher than normal. Biogen Idec jumped on positive Alzheimer's study results.